The limited protection despite the immunogenicity of the formulation [13, 43] can be explained by the ability of sporozoites to evade the immune response in the liver, since the vaccine only targets the Plasmodium falciparum Circumsporozoite Protein (CSP) a sporozoite and early liver stage antigen, facing the possibility that a single sporozoite that evades the immune system could lead to a blood stage infection and clinical malaria [44, 45]. Here, DNAJC5 is linked to infection.